ofloxacin has been researched along with Vaginosis, Bacterial in 5 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Vaginosis, Bacterial: Polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli. It remains unclear whether the initial pathogenic event is caused by the growth of anaerobes or a primary decrease in lactobacilli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Uncomplicated pelvic inflammatory disease (PID) is a common disease caused by numerous pathogens: sexually transmitted infections (such as Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium), anaerobes, and other organisms from the vaginal flora." | 6.74 | Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. ( Judlin, P; Thiebaugeorges, O, 2009) |
| "Women with clinically diagnosed cervicitis and BV received doxycycline and ofloxacin and were randomized to treatment with metronidazole gel or placebo." | 5.10 | Interrelationships of bacterial vaginosis and cervical inflammation. ( Schwebke, JR; Weiss, HL, 2002) |
| "Uncomplicated pelvic inflammatory disease (PID) is a common disease caused by numerous pathogens: sexually transmitted infections (such as Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium), anaerobes, and other organisms from the vaginal flora." | 2.74 | Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. ( Judlin, P; Thiebaugeorges, O, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Judlin, P | 1 |
| Thiebaugeorges, O | 1 |
| Domingues, D | 1 |
| Távora Tavira, L | 1 |
| Duarte, A | 1 |
| Sanca, A | 1 |
| Prieto, E | 1 |
| Exposto, F | 1 |
| Chandeying, V | 1 |
| Skov, S | 1 |
| Kemapunmanus, M | 1 |
| Law, M | 1 |
| Geater, A | 1 |
| Rowe, P | 1 |
| Kane, KY | 1 |
| Pierce, R | 1 |
| Schwebke, JR | 1 |
| Weiss, HL | 1 |
1 review available for ofloxacin and Vaginosis, Bacterial
| Article | Year |
|---|---|
Clinical inquiries. What are the most effective treatments for bacterial vaginosis in nonpregnant women?
Topics: Administration, Oral; Adult; Antifungal Agents; Clindamycin; Evidence-Based Medicine; Female; Guidel | 2001 |
3 trials available for ofloxacin and Vaginosis, Bacterial
| Article | Year |
|---|---|
Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study.
Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Female; Humans; Levofloxacin; Metronidazole; Ofl | 2009 |
Evaluation of two clinical protocols for the management of women with vaginal discharge in southern Thailand.
Topics: Adult; Anti-Infective Agents; Candidiasis, Vulvovaginal; Clinical Protocols; Doxycycline; Female; Go | 1998 |
Interrelationships of bacterial vaginosis and cervical inflammation.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Bacterial Agents; Anti-Infective Agents; | 2002 |
1 other study available for ofloxacin and Vaginosis, Bacterial
| Article | Year |
|---|---|
Genital mycoplasmas in women attending a family planning clinic in Guiné-Bissau and their susceptibility to antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Resistance, | 2003 |